Zihao Liu
Zihao Liu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Lifeng Yan
Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC Division of Life Sciences and Medicine University of Science and Technology of China Jinzai road 96 Hefei Anhui 230026 P.R. China
2 shared publications Dalong Yin
Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital, Division of Life Sciences and Medicine
1 shared publication- Dalong Yin
Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, Anhui, 230001, China; Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, Anhui, 230001, China
1 shared publication Hao He
Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital, Division of Life Sciences and Medicine
1 shared publicationHuiping Dang
Hefei National Laboratory for Physical Sciences at the Microscale, CAS Key Laboratory of Soft Matter Chemistry and Department of Chemical Physics
1 shared publicationJingfei Li
Department of General Surgery, Anhui Provincial Hospital
1 shared publication
Latest Publications
- 1 July 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (30) , 16619-16627
Precision Visualization of Surgical Margins and Depth Imaging Performance in Orthotopic Hepatocellular Carcinoma Using Galactose-Targeted NIR-II Fluorescence Nanoprobe
Accurate identification of tumor margins during liver cancer resection is crucial for improving prognosis and reducing postoperative complications. This study investigated the feasibility of using a galactose-targeted nanofluorescent probe known as Gal-OH-BDP NPs (GOB NPs), which emits in the NIR-II window, for fluorescence imaging of orthotopic hepatocellular carcinoma in animal models. In vitro imaging was performed with Intralipid emulsion and chicken breast to assess the tissue penetration depth of the GOB NPs and ICG in the NIR window. In vivo NIR-I/II imaging was conducted in orthotopic liver tumor animal models. Pathological validation confirmed that intratumoral injection of GOB NPs resulted in targeted accumulation within liver cancer tissue. Quantitative image analysis revealed that GOB NPs-mediated NIR-II imaging exhibited the highest fluorescence intensity at the tumor site and the lowest background fluorescence in the liver, thus resulting in the highest tumor-to-normal liver tissue ratio (TNR) and the highest tumor margin resolution. Additionally, GOB NPs-mediated NIR-II imaging maintained effective tumor margin visibility at a depth of 8 mm, whereas ICG-mediated NIR-I/II imaging demonstrated effective detection depths limited to 2 and 5 mm, respectively. Following intravenous injection, the GOB NPs exhibited negative staining, thus clearly delineating the tumor boundaries and achieving a high contrast between the tumor and liver tissues.
- 1 July 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (30) , 16619-16627
Precision Visualization of Surgical Margins and Depth Imaging Performance in Orthotopic Hepatocellular Carcinoma Using Galactose-Targeted NIR-II Fluorescence Nanoprobe
Accurate identification of tumor margins during liver cancer resection is crucial for improving prognosis and reducing postoperative complications. This study investigated the feasibility of using a galactose-targeted nanofluorescent probe known as Gal-OH-BDP NPs (GOB NPs), which emits in the NIR-II window, for fluorescence imaging of orthotopic hepatocellular carcinoma in animal models. In vitro imaging was performed with Intralipid emulsion and chicken breast to assess the tissue penetration depth of the GOB NPs and ICG in the NIR window. In vivo NIR-I/II imaging was conducted in orthotopic liver tumor animal models. Pathological validation confirmed that intratumoral injection of GOB NPs resulted in targeted accumulation within liver cancer tissue. Quantitative image analysis revealed that GOB NPs-mediated NIR-II imaging exhibited the highest fluorescence intensity at the tumor site and the lowest background fluorescence in the liver, thus resulting in the highest tumor-to-normal liver tissue ratio (TNR) and the highest tumor margin resolution. Additionally, GOB NPs-mediated NIR-II imaging maintained effective tumor margin visibility at a depth of 8 mm, whereas ICG-mediated NIR-I/II imaging demonstrated effective detection depths limited to 2 and 5 mm, respectively. Following intravenous injection, the GOB NPs exhibited negative staining, thus clearly delineating the tumor boundaries and achieving a high contrast between the tumor and liver tissues.
- Open Access
- 12 January 2024
- Published by World Scientific Pub Co Pte Ltd in Journal of Innovative Optical Health Sciences
- Vol. 17 (01)
NIR-II fluorescence imaging in liver tumor surgery: A narrative review
In liver tumor surgery, the recognition of tumor margin and radical resection of microcancer focis have always been the crucial points to reduce postoperative recurrence of tumor. However, naked-eye inspection and palpation have limited effectiveness in identifying tumor boundaries, and traditional imaging techniques cannot consistently locate tumors in real time. As an intraoperative real-time navigation imaging method, NIR fluorescence imaging has been extensively studied for its simplicity, reliable safety, and superior sensitivity, and is expected to improve the accuracy of liver tumor surgery. In recent years, the research focus of NIR fluorescence has gradually shifted from the first near-infrared window (NIR-I, 700–900 nm) to the second near-infrared window (NIR-II, 1000–1700[ ]nm). Fluorescence imaging in NIR-II reduces the scattering effect of deep tissue, providing a preferable detection depth and spatial resolution while significantly eliminating liver autofluorescence background to clarify tumor margin. Developing fluorophores combined with tumor antibodies will further improve the precision of fluorescence-guided surgical navigation. With the development of a bunch of fluorophores with phototherapy ability, NIR-II can integrate tumor detection and treatment to explore a new therapeutic strategy for liver cancer. Here, we review the recent progress of NIR-II fluorescence technology in liver tumor surgery and discuss its challenges and potential development direction.
- 12 January 2024
- Published by World Scientific Pub Co Pte Ltd in Journal of Innovative Optical Health Sciences
- Vol. 17 (01)
Open AccessNIR-II fluorescence imaging in liver tumor surgery: A narrative review
In liver tumor surgery, the recognition of tumor margin and radical resection of microcancer focis have always been the crucial points to reduce postoperative recurrence of tumor. However, naked-eye inspection and palpation have limited effectiveness in identifying tumor boundaries, and traditional imaging techniques cannot consistently locate tumors in real time. As an intraoperative real-time navigation imaging method, NIR fluorescence imaging has been extensively studied for its simplicity, reliable safety, and superior sensitivity, and is expected to improve the accuracy of liver tumor surgery. In recent years, the research focus of NIR fluorescence has gradually shifted from the first near-infrared window (NIR-I, 700–900 nm) to the second near-infrared window (NIR-II, 1000–1700[ ]nm). Fluorescence imaging in NIR-II reduces the scattering effect of deep tissue, providing a preferable detection depth and spatial resolution while significantly eliminating liver autofluorescence background to clarify tumor margin. Developing fluorophores combined with tumor antibodies will further improve the precision of fluorescence-guided surgical navigation. With the development of a bunch of fluorophores with phototherapy ability, NIR-II can integrate tumor detection and treatment to explore a new therapeutic strategy for liver cancer. Here, we review the recent progress of NIR-II fluorescence technology in liver tumor surgery and discuss its challenges and potential development direction.